Biome | Jotup

Biome Launches Innovative Acute Coronary Syndrome (ACS) Module to Enhance Care Delivery

Retrieved on:

Martedì, Aprile 16, 2024

Healthcare systems face the ongoing challenge of managing bed capacity while striving to provide high-quality patient care and achieve excellent clinical outcomes.

Key Points:

Healthcare systems face the ongoing challenge of managing bed capacity while striving to provide high-quality patient care and achieve excellent clinical outcomes.
Biome's new ACS module is designed to assist healthcare systems in managing the complexities associated with chest pain care.
As hospitals increasingly pursue accreditation for chest pain center certification, having immediate access to performance data is critical.
These advanced insights equip leaders with the insights they need to maximize operational capacity and enhance patient outcomes, ultimately leading to improved healthcare experience for patients.

Biome Analytics Unveils Next-Generation Echo Quality and Patient Monitoring Tool

Retrieved on:

Mercoledì, Ottobre 4, 2023

"Biome is dedicated to transforming healthcare through innovative technology solutions," said Matthew Esham, VP of Analytics at Biome. "The release of Biome’s Surveillance Manager is a testament to our commitment to empowering healthcare providers with the advanced data and insight they need to serve more patients, provide better care, and achieve greater margin-- capabilities that drive operational efficiency, improve quality outcomes and enhance patient care."

Key Points:

Biome Analytics, a leading innovator in cardiovascular performance improvement, is excited to announce the immediate availability of the Biome Surveillance Manager™, its advanced Cardiac Ultrasound Management tool.
Ensuring adherence to protocols and delivering high-quality results are crucial for the early detection of cardiac diseases, better patient outcomes, and lower costs.
Using unique benchmarks, Biome Surveillance Manager monitors previous study comparisons, calculated ejection fractions, and other critical metrics, helping operators improve their quality and reduce variation.
"Biome is dedicated to transforming healthcare through innovative technology solutions," said Matthew Esham, VP of Analytics at Biome.

UES Expands Ecological Expertise with Acquisition of Biome Consulting Group

Retrieved on:

Giovedì, Settembre 7, 2023

ORLANDO, Fla., Sept. 7, 2023 /PRNewswire/ -- UES, a national leading engineering and consulting company, has acquired Biome Consulting Group, an ecological consulting firm located in the Central Gulf Coast region of Florida. Biome conducts a wide variety of applied ecological studies and environmental regulatory compliance-related consulting services throughout the Southeastern U.S. and Caribbean.

Key Points:

The Nation's Fastest-Growing Engineering and Consulting Firm Makes Strategic Acquisition of Pensacola, FL-based Firm
ORLANDO, Fla., Sept. 7, 2023 /PRNewswire/ -- UES, a national leading engineering and consulting company, has acquired Biome Consulting Group, an ecological consulting firm located in the Central Gulf Coast region of Florida.
Biome conducts a wide variety of applied ecological studies and environmental regulatory compliance-related consulting services throughout the Southeastern U.S. and Caribbean.
Biome's expertise includes consulting on thousands of private development projects, from single family residential through commercial and residential development, as well as government and industrial work.
"The acquisition of Biome further expands our ecological and environmental services of our region, and we are excited to add their expert staff to Team UES," said Kushner, P.E., president of the North Florida region.

Adare Pharma Solutions announces divestiture of postbiotics pioneer Adare Biome to dsm-firmenich

Retrieved on:

Lunedì, Luglio 3, 2023

Gut, Nutrition, EV, Health, Adare, Research, Science, CDMO, Beauty, Postbiotic, Animal, Dietary supplement, Acquisition, Biome, Volvo Business Units, Pet, Growth, Fine chemical

PHILADELPHIA, July 3, 2023 /PRNewswire/ -- Adare Pharma Solutions, a global technology-driven CDMO focused on oral dosage forms, today announced the completion of its divestiture of its Adare Biome business unit, a pioneer in the development and manufacturing of postbiotics, to dsm-firmenich, innovators in nutrition, health, and beauty.

Key Points:

PHILADELPHIA, July 3, 2023 /PRNewswire/ -- Adare Pharma Solutions, a global technology-driven CDMO focused on oral dosage forms, today announced the completion of its divestiture of its Adare Biome business unit, a pioneer in the development and manufacturing of postbiotics, to dsm-firmenich, innovators in nutrition, health, and beauty.
Tom Sellig, CEO of Adare Pharma Solutions, commented: "dsm-firmenich is the ideal company to take Adare Biome to the next level and realize the growth potential of postbiotics.
This divestiture will provide Adare Pharma Solutions with additional resources for our core CDMO business and allow us to further grow our position as a world-class outsourcing partner to the pharmaceutical industry."
We are excited to welcome the Adare Biome people to the dsm-firmenich family and about the new opportunities this move will unlock.

Adare Pharma Solutions announces divestiture of postbiotics pioneer Adare Biome to dsm-firmenich

Retrieved on:

Lunedì, Luglio 3, 2023

Gut, Nutrition, EV, Health, Adare, Research, Science, CDMO, Beauty, Postbiotic, Animal, Dietary supplement, Acquisition, Biome, Volvo Business Units, Pet, Growth, Fine chemical

PHILADELPHIA, July 3, 2023 /PRNewswire/ -- Adare Pharma Solutions, a global technology-driven CDMO focused on oral dosage forms, today announced the completion of its divestiture of its Adare Biome business unit, a pioneer in the development and manufacturing of postbiotics, to dsm-firmenich, innovators in nutrition, health, and beauty.

Key Points:

PHILADELPHIA, July 3, 2023 /PRNewswire/ -- Adare Pharma Solutions, a global technology-driven CDMO focused on oral dosage forms, today announced the completion of its divestiture of its Adare Biome business unit, a pioneer in the development and manufacturing of postbiotics, to dsm-firmenich, innovators in nutrition, health, and beauty.
Tom Sellig, CEO of Adare Pharma Solutions, commented: "dsm-firmenich is the ideal company to take Adare Biome to the next level and realize the growth potential of postbiotics.
This divestiture will provide Adare Pharma Solutions with additional resources for our core CDMO business and allow us to further grow our position as a world-class outsourcing partner to the pharmaceutical industry."
We are excited to welcome the Adare Biome people to the dsm-firmenich family and about the new opportunities this move will unlock.

Biome Analytics partners with Ascend.io to eliminate $10B in wasteful spend from U.S. healthcare industry

Retrieved on:

Giovedì, Giugno 22, 2023

Partnership, SQL, Hospital, Intelligence, Ascend, Patient, Machine learning, Performance Network Theatre, Growth, Ecosystem, Automation, Data science, Nursing, Biome

MENLO PARK, Calif., June 22, 2023 /PRNewswire/ -- Ascend.io, the leader in data pipeline automation, today announced that it is enabling Biome Analytics, a clinical performance improvement solutions provider, to help Biome overhaul cardiac healthcare delivery and improve outcomes for both patients and healthcare providers.

Key Points:

Cardiovascular care accounts for a significant and growing share of U.S. healthcare system spending, costing over $216 billion per year .
"Through our partnership with Biome Analytics, we're leveraging the power of data pipeline automation to make a profound impact on healthcare," said Jon Osborn, Field CTO of Ascend.io.
It's not just about accelerating digital transformation – it's about fostering a paradigm shift in how we understand and approach healthcare.
We're proud to support Biome Analytics on this mission, demonstrating the critical role of data in driving efficiency and improving patient outcomes in the healthcare industry."

Biome Extends and Enhances its commitment to Security, Data Governance, and Compliance

Retrieved on:

Giovedì, Maggio 25, 2023

Technology, Security, Health Technology, Cardiology, Practice Management, Biotechnology, Biometrics, Health, Data Management, SOC, Privacy, SOC 2, Physician, Machine learning, Artificial intelligence, Medical device, Biome

This achievement demonstrates the company's unwavering commitment to privacy and the protection of client clinical and financial data.

Key Points:

This achievement demonstrates the company's unwavering commitment to privacy and the protection of client clinical and financial data.
SOC 2 compliance is of paramount importance to Biome Analytics' clients, who rely on the company's proprietary machine learning-driven, human-enabled performance solutions to engage and align and drive the delivery of high-performance cardiovascular care.
"Biome is dedicated to helping our clients achieve superior clinical and financial outcomes," said Rakan Khaki, COO at Biome Analytics.
By leveraging data assets and engaging physicians, Biome Analytics accelerates performance improvement and enables its clients to achieve superior clinical and financial outcomes.

Biome Renewables completes successful Wind Tunnel Validation Testing on FeatherEdge® serration technology at DTU Risø's Poul la Cour Tunnel

Retrieved on:

Martedì, Maggio 9, 2023

Noise, Wind, Poul, Engineering, Energy, Ryan Church, DTU, Electric motor, Biome

AMSTERDAM, May 9, 2023 /PRNewswire/ -- Biome Renewables (Biome) has announced the results of wind tunnel test measurements carried out on their novel FeatherEdge® trailing edge serration technology, reporting a promising noise reduction of 8 dB off a baseline Risø B1-18 airfoil operating under similar conditions. The testing took place January 2023 in the Poul la Cour Tunnel (PLCT) at DTU Wind Energy, Risø Campus, Roskilde, Denmark.

Key Points:

The testing took place January 2023 in the Poul la Cour Tunnel (PLCT) at DTU Wind Energy, Risø Campus, Roskilde, Denmark.
To validate the technology, Biome entrusted DTU and their state-of-the-art wind tunnel to complete a measurement campaign of aerodynamic coefficients and noise measurements.
With turbulence intensity
Biome Contact: Ryan Church, CEO, [email protected] , https://www.biome-renewables.com/featheredge ; DTU Contact: Christian Bak, Professor, Airfoil and Rotor Design, [email protected] // https://www.plct.dk/

The Responsible Flushing Alliance Welcomes Guy & O'Neill and biom in Bolstering Efforts in Consumer Education on Proper Flushing Habits

Retrieved on:

Lunedì, Maggio 8, 2023

Habit, Education, Public, Innovation, Research, Wet wipe, Charlie Brooker's Weekly Wipe, Sanitation, Biome, Water, Growth, City, Guy, System, SVP, Environment, RFA, Social media, CPO, Tea

SEATTLE, May 8, 2023 /PRNewswire-PRWeb/ -- Today, the Responsible Flushing Alliance (RFA) announced that Guy & O'Neill and biom have joined its coalition of wipes manufacturers, wastewater treatment groups, and public health advocates working to mitigate the improper flushing of non-flushable personal care products.

Key Points:

"Our 2023 campaign aims to increase consumer awareness of the 'Do Not Flush' symbol and promote proper flushing habits, and the addition of Guy & O'Neill and biom will propel these efforts even further," said RFA President Lara Wyss.
Partnering with the Responsible Flushing Alliance is an exciting opportunity for Guy & O'Neill to continue caring for our communities and infrastructures," Guy & O'Neill CEO Jeff Brooks stated.
Joy Campbell, SVP of Innovation at Guy & O'Neill stated, "We are eager to join the Responsible Flushing Alliance and industry peers in advancing consumer awareness of smart flushing habits.
The scientists and engineers at Guy & O'Neill are passionate about championing responsible flushing, as well as designing products that are safe to flush."

Gladskin Introduces GladskinMD Line for Inflammatory Skin Conditions

Retrieved on:

Martedì, Marzo 14, 2023

Health care, FAAD, Dysbiosis, Patient, Pediatrics, Education, Medicine, Atopic dermatitis, Nursing, Dermatology, Biome, MD

ENCINITAS, Calif., March 14, 2023 /PRNewswire/ -- Gladskin, the only skincare company in the US that uses endolysin science in its products, is pleased to announce the launch of its new GladskinMD line. GladskinMD offers biome therapeutic skincare products for patients seeking medical care for inflammatory skin conditions, including atopic dermatitis, and is available exclusively through dispensing healthcare providers.

Key Points:

GladskinMD offers biome therapeutic skincare products for patients seeking medical care for inflammatory skin conditions, including atopic dermatitis, and is available exclusively through dispensing healthcare providers.
The GladskinMD line launches with two essential products: Eczemact™ Flare Care Concentrate and Eczemact™ Barrier Restore MD.
Healthcare providers can learn about the skin microbiome's role in inflammatory skin conditions via Gladskin's new educational game, "Battle of the Biome," which leverages the neuroscience of gaming to motivate learning and enhance patient outcomes.
"Understanding the skin microbiome is important, but it can be hard to carve out time for education," said Gladskin President Skyler Stein.